Heron Therapeutics, Inc.
HRTX
$2.11
-$0.06-2.77%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.79M | -13.58M | -27.97M | -48.13M | -80.95M |
| Total Depreciation and Amortization | 2.35M | 2.49M | 2.63M | 2.77M | 2.87M |
| Total Amortization of Deferred Charges | 1.03M | 961.00K | 824.00K | 520.00K | 428.00K |
| Total Other Non-Cash Items | 14.49M | 15.20M | 17.08M | 20.57M | 27.02M |
| Change in Net Operating Assets | -31.97M | -27.60M | -858.00K | 3.42M | 7.23M |
| Cash from Operations | -21.88M | -22.53M | -8.29M | -20.84M | -43.41M |
| Capital Expenditure | -1.82M | -1.71M | -1.32M | -1.68M | -1.32M |
| Sale of Property, Plant, and Equipment | 69.00K | 27.00K | 13.00K | 13.00K | 13.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.46M | 20.39M | -235.00K | -27.06M | -16.25M |
| Cash from Investing | 19.71M | 18.71M | -1.54M | -28.73M | -17.56M |
| Total Debt Issued | -- | -- | 0.00 | 24.35M | 24.35M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 940.00K | 940.00K | 718.00K | 30.46M | 30.66M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 53.00K | 0.00 | -2.00K | -310.00K | -684.00K |
| Cash from Financing | 993.00K | 940.00K | 716.00K | 54.50M | 54.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.18M | -2.88M | -9.12M | 4.92M | -6.64M |